nevirapine, zidovudine and lamivudine

Similar documents
nevirapine, stavudine and lamivudine

Efavirenz, stavudine and lamivudine

d4t-3tc-nvp stavudine lamivudine nevirapine Morning: d4t-3tc-nvp (Combined tablet) Evening: d4t and 3TC (2 separate tablets)

ANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL

INITIATING ART IN CHILDREN: Follow the six steps

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUOVIR N * (Lamivudine/Zidovudine /Nevirapine 150/ 300/200 mg)

Clinical Case Scenario. HIVeEducation Workshop, Sint Maarten 2009

PATIENT INFORMATION LEAFLET

Elements for a public summary

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

Continuing Education for Pharmacy Technicians

treatment during pregnancy and breastfeeding

MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen)

Nevirapine 200mg Tablet WHOPAR part 3 May 2005 Updated: May 2016 PACKAGE LEAFLET

Further publications can be obtained from the HIV/AIDS Unit, Department of Communicable Diseases, World Health Organization, Regional Office for

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

Abacavir Sulfate, Lamivudine and Zidovudine Tablets WHOPAR Part 3 05/2009, version mg/150mg/300mg (Ranbaxy Laboratories Ltd), HA324

Principles of Antiretroviral Therapy

VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

PATIENT INFORMATION LEAFLET

NEVIRAPINE RBX Nevirapine Tablets

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

TRIZIVIR film coated tablets

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

LTBI Videos-Treatment

KIVEXA abacavir (as sulfate) and lamivudine

What is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?

MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015

Viramune XR Extended-Release Tablets Nevirapine

Package leaflet: Information for the user. Abacavir/Lamivudine Lupin 600 mg/300 mg film-coated tablets abacavir/lamivudine

Package leaflet: Information for the user. Abacavir/Lamivudine 600 mg/300 mg Film-Coated Tablets abacavir/lamivudine

PATIENT INFORMATION LEAFLET AMLOC RANGE

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

PATIENT INFORMATION LEAFLET

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

Hepatitis C: Module Options for genotype 1a and 1b pros and cons

Trizivir Lamivudine, zidovudine, abacavir (as sulphate)

PATIENT INFORMATION LEAFLET

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.

What this medicine is used for

AZT (zidovudine, Retrovir)

3TC (lamivudine, Epivir)

Section 4: Side effects of ARVs. 4.1 Introduction. 4.2 Aims for this section

Nevirapine Alphapharm

3TC (lamivudine, Epivir)

Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate

ADVANCED CLINICAL CARE JOB AIDES VERSION1- MARCH 2018

Newly diagnosed HIV patient. Dr. Heila Redpath 06 FEBRUARY 2014

A Genetic Test to Screen for Abacavir Hypersensitivity Reactions

TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers

PEOPLE ARE TAKING WORKS FOR THEM. Ask your healthcare provider if it could work for you, too. a medication that

GlaxoSmithKline Research Triangle Park, NC the ViiV Healthcare group of companies. All rights reserved. ZGN:XPI

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

PATIENT INFORMATION LEAFLET FOR FEDALOC 30 mg / 60 mg SR TABLETS. Please read this leaflet carefully before you start taking FEDALOC tablets.

Sorafenib (Nexavar ) For thyroid carcinoma

Antiretroviral Pharmacovigilance Training Course. Dar es Salaam, United Republic of Tanzania

Nevirapine 200mg Tablet WHOPAR part 4 May 2005 Section 7 updated: May 2016 SUMMARY OF PRODUCT CHARACTERISTICS

BACTRIM tablets PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1 WHAT BACTRIM IS AND WHAT IT IS USED FOR

FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES

Medication Guide. VIDEX EC (VY-dex Ee-see) (didanosine, also known as ddi) Delayed-Release Capsules Enteric-Coated Beadlets

PACKAGE LEAFLET. Lamivudine/Zidovudine 150/300 mg Tablets WHOPAR part 3 04/2009, version 1.0 Section 6 updated: June 2017 (Mylan Lab.

HYPERSENSITIVITY REACTION

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

50 mg dolutegravir (as dolutegravir sodium) / 600 mg abacavir (as abacavir sulfate) / 300mg lamivudine

Clinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years. SAHIVCS - CME 13/06/15 DR.Henry Sunpath

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

B. PACKAGE LEAFLET 1

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

Film-coated tablets 50 mg dolutegravir (as dolutegravir sodium) / 600 mg abacavir (as abacavir sulfate) / 300mg lamivudine

Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications

Vemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

ZIAGEN tablets 300 mg tablets

ATORIS 10, 20, 40 mg film-coated tablets

PACKAGE LEAFLET INFORMATION FOR THE USER. Cimetidine 200mg Tablets Cimetidine 400mg Tablets Cimetidine 800mg Tablets (Cimetidine)

Haematology Mycophenolate Mofetil Information for patients

104 MMWR December 17, 2004

PATIENT INFORMATION LEAFLET

Before you take COMBIVIR tablets. When you must not take them

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Difference of opinion? Michelle Moorhouse 24 Sep 2014

Package leaflet: Information for the patient. Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone

The prevalence of Stevens Johnson Syndrome caused by antiretroviral in hospitalized patients at Dr. Hasan Sadikin General Hospital Bandung

PATIENT INFORMATION LEAFLET

PRODUCT MONOGRAPH TARCEVA. erlotinib hydrochloride tablets. erlotinib 25, 100, 150 mg

NEOFEN 60 mg suppository

CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX

Selecting an Initial Antiretroviral Therapy (ART) Regimen

REVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study

Lamivudine, Nevirapine, and Zidovudine

Important Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection

MODERN ART FOR AFRICA

1. and it is more than 12 hours until your next dose, take the missed dose and continue with your normal schedule

PATIENT INFORMATION LEAFLET

Transcription:

nevirapine, zidovudine and lamivudine a fixed dose ART combination for HIV treatment http://www.aidsmap.com/hatip

nevirapine. zidovudine and lamivudine (non-fixed dose) 2 Information on starting treatment with nevirapine + zidovudine + lamivudine

Lead in dosing for the first 14 days (1) Nevirapine must be given at a lower dose (one tablet per day) for the first 14 days Treatment must never start at full dose Increased risk of serious rash and life threatening reaction if used at full dose Nevirapine dose must not increase until serious rash declines http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 3

nevirapine. zidovudine and lamivudine (non-fixed dose) 4 Lead in dosing for the first 14 days (2) Nevirapine 200mg once daily + Zidovudine/lamivudine combination tablet twice daily, 12 hours apart

Dosing schedule after day 14 Nevirapine 200mg (one tablet) twice daily + ZDV/3TC combination tablet twice daily Take all medication twice daily, 12 hours apart http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 5

nevirapine. zidovudine and lamivudine (non-fixed dose) 6 Nevirapine side effects and monitoring Rash Higher risk periods: Rash: first month, Hepatitis: first six months Rash appears on arms and torso, severe in up to 10% Stevens-Johnson syndrome: severe skin eruption, peeling, fluid loss. Stop treatment immediately and refer to district hospital. When treatment resumes, use efavirenz instead of nevirapine. Rash and/or hepatitis may also be caused by isoniazid and rash by cotrimoxazole Hypersensitivity reaction: rash preceded by fever, joint pain and swelling, hepatitis. Stop all treatment immediately. When treatment resumes, use efavirenz instead of nevirapine.

nevirapine. zidovudine and lamivudine (non-fixed dose) 7 Nevirapine and hepatitis Severe liver enzyme elevations: symptoms jaundice, pain in liver & abdomen, nausea, vomiting Stop treatment until normalised or change to another drug (efavirenz or abacavir) or refer to district hospital for treatment change At higher risk: female, older age, high alcohol use, hepatitis B or C coinfection

nevirapine. zidovudine and lamivudine (non-fixed dose) 8 Other side effects (1) Occasional but life threatening Pancreatitis Sharp pain below stomach, nausea, vomiting, fever Very rare with these drugs linked to lamivudine Lactic acidosis Rare, linked to zidovudine or stavudine Fatigue, abdominal pain, nausea and vomiting, muscle weakness and pain, weight loss, breathing difficulty. Refer to doctor/district hospital. Stop treatment and use bicarbonate, fluid, breathing support Refer to district hospital level to resume treatment, switch from zidovudine to tenofovir if available Occasional, needs ongoing monitoring Neutropenia If neutrophil count < 500/ml, consider switch from ZDV

nevirapine. zidovudine and lamivudine (non-fixed dose) 9 Other side effects (2) Possible long-term Fat loss from limbs and face (lipoatrophy) (best to switch from zidovudine to tenofovir or abacavir) Anaemia Caused by ZDV High risk in patients with anaemia before treatment, women may be at higher risk Monitor haemoglobin, or for paleness, tiredness Severe anaemia blood transfusion, switch from ZDV if possible Moderate anaemia reduce ZDV dose, discontinue fixed dose combination tablet and use separate formulations for each drug until anaemia improves Long-term reduced ZDV dose not recommended, will lead to treatment failure, resistance

nevirapine. zidovudine and lamivudine (non-fixed dose) 10 Other side effects (3) jáäç=éêçääéãë=ó êé~ëëìêé=íü~í=íüéó=~êé=åçí=ëéêáçìë Headache Common in first weeks of ZDV treatment use headache remedies, refer to doctor/district level if it lasts beyond first month Nausea Common in first weeks of ZDV treatment, may be reduced if taken with food Fatigue Common in first 4-6 weeks of ZDV treatment, refer to doctor/district level if it lasts longer Blue/black nails Quite common with ZDV, not harmful, reassure

nevirapine. zidovudine and lamivudine (non-fixed dose) 11 Drug interactions (1) Avoid nevirapine whilst receiving rifampicin for TB treatment Use antifungals other than ketoconazole Clarithromycin and nevirapine: monitor liver enzymes; CL may increase NVP levels Blood levels of beta blockers, doxycycline, felodopine, griseofulvin, metronidazole, nifedipine, quinidine, steroids, theophylline, and warfarin may be decreased in patients taking nevirapine-containing regimens

nevirapine. zidovudine and lamivudine (non-fixed dose) 12 Drug interactions (2) Cotrimoxazole may increase risk of neutropenia and anaemia when taken with ZDV Anti-convulsants: ZDV reduces phenytoin levels, valproic acid increases ZDV levels Nevirapine may reduce oral contraceptive levels

nevirapine. zidovudine and lamivudine (non-fixed dose) 13 Pregnancy and breastfeeding These drugs unlikely to harm unborn child but evidence is limited The use of triple therapy substantially reduces the risk of mother to child transmission during pregnancy Treatment during the first trimester may carry higher risk of harm to unborn child Effectiveness of preventing transmission through breastfeeding unknown The fixed dose tablet must not be used for treatment of children

nevirapine. zidovudine and lamivudine (non-fixed dose) 14 Test questions 1. What are the names of the drugs? 2. How are the drugs dosed during the first 14 days? 3. What are the most serious side effects and how should these be dealt with? 4. What are the important drug interactions? 5. What is the effect of nevirapine on the contraceptive pill? 6. Is this combination safe for pregnant women?